Navigation Links
Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study
Date:9/1/2008

MUNICH, Germany, September 1 /PRNewswire-FirstCall/ -- Biosensors International Group, Ltd ("Biosensors", "Company"), (Bloomberg: BIG:SP), (Singapore:B20) today announced that a next-generation drug-eluting stent, developed by Biosensors, has demonstrated equal safety and efficacy as compared to Johnson & Johnson's industry leading drug-eluting stent, CYPHER SELECT(TM) ("Cypher"), based upon nine-month clinical and angiographic follow-up data. The results of the landmark study were presented today at the 2008 European Society of Cardiology Congress and published concurrently on-line by the prestigious UK medical journal The Lancet.

LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) is the first head-to-head randomized study between the two drug-eluting stent systems (DES) in a 'real world, all comers' population using clinical results as its primary endpoint.

This multi-centre European study randomized 1,707 patients eligible for percutaneous coronary intervention (PCI) for symptomatic coronary disease to receive either a Biosensors Biolimus-eluting DES with an abluminal biodegradable polymer coating, or a Cypher Sirolimus-eluting DES with a durable polymer. In total, 2,472 coronary lesions were treated. Inclusion criteria were broad, reflecting routine clinical practice, without limitations regarding type of coronary vessel, lesion length or number of treated lesions. Patient conditions known as "off-label indications", including acute coronary syndromes, saphenous vein grafts and previously treated lesions were also included in the trial.

The primary endpoint of the study was non-inferiority of the composite of cardiac death, myocardial infarction, and clinically-driven target vessel revascularization ("TVR") at nine months follow-up. In addition, 25 percent of all patients were randomly assigned to undergo angiographic follow-up at nine months. The principal endpoint of the pre-specified angiographic sub-group was in-s
'/>"/>

SOURCE Biosensors International Group, Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
2. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
7. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
8. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 FDNA® ... analysis will exhibit at the 2014 ASHG meeting, booth ... FDNA will present the latest version of Face2Gene - ... facial analysis technology. Face2Gene facilitates the detection of facial ... facial photos. The new version of Face2Gene ...
(Date:9/23/2014)... HACKENSACK, N.J. , Sept. 23, 2014   ... million in a planned $7 million Series A funding ... participation from Med-Metrix. COTA is the first big data ... outcomes data and cost analysis for cancer care in ... funds will be used to expand development of the ...
(Date:9/23/2014)... 2014 Cerevast Therapeutics Inc., a privately ... of the first interim analysis of its ongoing ... Clotbust ER TM ultrasonic headframe ... independent Data Safety Monitoring Board (DSMB) has recommended ... "Clearing the pre-specified futility threshold and four independent ...
Breaking Medicine Technology:FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 2Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 3
... May 3, 2012 Valeant Pharmaceuticals International, Inc. ... announced today that Valeant has agreed to acquire ... specialty pharmaceutical company focused on skincare products, for ... attainment of future revenue targets.  University Medical,s main ...
... Medical Group Inc. (Nasdaq: WWIN ) ("Winner ... retailer of high-quality medical dressings and consumer products made ... financial results for its second quarter 2012 on May ... conference call to discuss these results. Date ...
Cached Medicine Technology:Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical 2Winner Medical Group Inc. to Host Second Quarter 2012 Earning Conference Call on Thursday, May 10, 2012 at 9:00 p.m. EDT 2
(Date:9/23/2014)... who are already obese as teenagers could grow up ... peers of normal weight. So says Petter Lundborg of ... Rooth of Linneas University and Lund University, all in ... United Kingdom and the United States, and the results ... , The researchers analyzed large-scale data of 145,193 Swedish-born ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has recently ... services in Vancouver, BC. The company will provide services ... small maintenance project or a large-scale new installation project, ... the needs of the individual commercial client. Pro Ace ... an affordable price. As a result, businesses of all ...
(Date:9/23/2014)... 2014 The Sloane Clinic™, a ... and Malaysia providing advanced aesthetic dermatology and cosmetic ... its impressive skin care repertoire. Specially formulated with ... against the evil forces of aging, acne and ... this new addition is revolutionizing the way we ...
(Date:9/23/2014)... New York, New York (PRWEB) September 23, 2014 ... move forward in courts around the country, Bernstein Liebhard ... District Court, Middle District of Florida on September 19th, ... claims from a case filed in that jurisdiction on ... breast growth) and other complications due to his use ...
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... drugs while in the hospital for a hemorrhagic stroke -- ... four times more likely to survive than people who weren,t ... taking the commonly used drugs known as statins were also ... a rehabilitation facility, the study reports. When it comes ...
Breaking Medicine News(10 mins):Health News:Note to young men: Fat doesn't pay 2Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3
... to be under-enrolled in cancer clinical trials, according to a ... CANCER , a peer-reviewed journal of the American Cancer ... to ensure that oncologists know the true effects of treatments ... National Institutes of Health called for clinical trials to include ...
... A local leading ... surgery and what benefits these techniques have for the patient. , ... Manchester, UK (PRWeb UK) 07 June, 2009 -- Cosmetic ... providers of cosmetic surgery than ever before. As a result there is an inherent danger ...
... June 7 There is no difference in mortality among ... received prompt bypass surgery or angioplasty compared to drug therapy ... with both conditions. The study, which was led by investigators ... published in the June 11 issue of the New ...
... ... clinic will be built in Belize City, Belize. , ... Sioux Falls, SD (Vocus) June 7, 2009 -- Children in Central ... today its first international children,s clinic will be built in Belize City, Belize. The new ...
... , NEW ORLEANS, June 6 Catholic health ministry leaders ... Catholic Health Assembly, "In Our Hands: Changing Ourselves, Our Communities, ... the Catholic Health Association of the United States (CHA), is ... across the nation. They come together to share their wisdom, ...
... ... leading organization of plastic surgeons indicates a 162 percent increase in cosmetic surgery since ... with new technologies to treat patients who want to improve their appearance without anyone ... ...
Cached Medicine News:Health News:Women under-represented in most cancer research 2Health News:Latest Developments In Facelift Surgery - Expert Opinion by Mr James Murphy 2Health News:Latest Developments In Facelift Surgery - Expert Opinion by Mr James Murphy 3Health News:Death rates same for diabetes and heart disease patients receiving drug therapy or surgery 2Health News:Sanford Health Announces Sanford Children's Clinic Belize 2Health News:Sanford Health Announces Sanford Children's Clinic Belize 3Health News:Sanford Health Announces Sanford Children's Clinic Belize 4Health News:2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 2Health News:2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 3Health News:Sacramento Plastic Surgeon Charles Perry, MD Embraces Innovative Technologies to Improve Appearance and Self-Esteem 2Health News:Sacramento Plastic Surgeon Charles Perry, MD Embraces Innovative Technologies to Improve Appearance and Self-Esteem 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: